Login to Your Account

J&J Buys $444M Stake in Crucell; Focus on Flu Vaccine and mAbs

By Cormac Sheridan

Tuesday, September 29, 2009
Shares in Crucell N.V. dipped Monday despite the addition of almost €302 million (US$441 million) to its balance sheet, following a strategic research alliance with Johnson & Johnson, which is acquiring an 18 percent stake in the company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription